Sa481 THE POTENTIAL ROLE OF PERIPHERAL NATURAL KILLER CELLS IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE OR COLORECTAL CANCER

The occurrence of natural killer cells and large granular lymphocytes (LGL) within the epithelium of colonic mucosa in children with inflammatory bowel disease (IBD) was compared to normal controls. Their numbers and localization within the epithelium from various regions of the colon were analyzed with immunohistochemical techniques using fluorescent, light and electron microscopy. The average number of natural killer cells and LGL in normal controls was 3.0±1.l per mn2. In contrast, there were no natural killer cells in the gut epithelium of children with IBD, irrespective of disease activity, whether the biopsy specimens were obtained from involved or uninvolved inflammatory regions of the gut, or the treatment status of the patients. However, the number of natural killer cells was normal in patients in remission with left-sided colitis. The lack of natural killer cells and LGL in the gut epithelium in children with IBD may be indicative of a possible genetic predisposition. The authors also present a new therapeutic strategy consisting of low dose interferon-alpha-2a that is efficacious in ameliorating ulcerative col iris and Crohn's disease and concomitantly increasing the number of natural killer cells and LGL in the gut.

Download Full-text

Abstract B71: Potential role of hemoglobin in colorectal cancer initiation in inflammatory bowel disease setting.

10.1158/1055-9965.disp12-b71 ◽

2012 ◽

Author(s):

Laura A. Franklin ◽

Joan C. Smith ◽

Billy R. Ballard ◽

Erin H. Seeley ◽

Mary K. Washington ◽

...

Keyword(s):

Colorectal Cancer ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Potential Role ◽

Cancer Initiation ◽

Inflammatory Bowel

Download Full-text

Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease

World Journal of Gastroenterology ◽

10.3748/wjg.v23.i18.3240 ◽

2017 ◽

Vol 23 (18) ◽

pp. 3240 ◽

Cited By ~ 4

Author(s):

James D Lord ◽

Donna M Shows

Keyword(s):

Inflammatory Bowel Disease ◽

Natural Killer Cells ◽

Natural Killer ◽

Bowel Disease ◽

Killer Cells ◽

Inflammatory Bowel

Download Full-text

N04 Knowledge, attitude and perception of inflammatory bowel disease patients towards colorectal cancer risk, its management and the role of healthcare providers: a cross-sectional study in the UK

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.988 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S659-S659

Author(s):

F Khan ◽

W Czuber-Dochan ◽

C Norton

Keyword(s):

Colorectal Cancer ◽

Inflammatory Bowel Disease ◽

Risk Management ◽

Cancer Risk ◽

Bowel Disease ◽

Initiation Time ◽

Cross Sectional ◽

Early Cancer Diagnosis ◽

Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC) and requires specialised cancer risk management. Although literature exists on general disease-related knowledge in IBD patients, limited studies have assessed IBD patients’ knowledge of CRC risk and its management. Consequently, patient perception of the role of a healthcare provider (HCP) in patient education of CRC risk and their attitude towards recommended risk management has not been assessed in UK IBD patients. Methods We conducted a cross-sectional online survey with IBD patients recruited via charity sources from April-July 2019. Adult patients (>18 years) with a confirmed diagnosis of IBD for 2 years and adequate command of English language were included. A self-designed and piloted questionnaire with open and closed-ended questions was used. Closed-ended data were analysed using descriptive statistics and open-ended responses were analysed using content analysis. Fischer’s exact test and bivariate logistic regression were used to test for association between knowledge and patient demographics. Results 92 participants, including 52.5% CD and 67.5% females, responded. 88% knew that IBD increases CRC risk. The mean fear of CRC risk (0–10 visual analogue scale) was 6.37 (SD ± 2.8). One-fifth were aware of colonoscopy as the best screening tool; 88% were unaware of screening initiation time. 90% would agree to their doctor’s recommendation of colonoscopy to ensure early cancer diagnosis and treatment. For dysplasia with 10% risk of CRC, 46.7% would not agree to colectomy mainly due to 10% risk of CRC not being high enough to undergo surgery. Forty-eight per cent of participants said that they never had a discussion about increased CRC risk in IBD with their doctor. Almost two-thirds were not informed about the role of screening/surveillance in cancer. Two-thirds were satisfied with the information provided by their HCP. Overall, patients desired more information about their individualised cancer risk and services available for managing the increased risk. Conclusion IBD patients are well informed about IBD-associated CRC risk, feared this risk greatly but were poorly aware of screening initiation time. HCP’s role in cancer knowledge dissemination was sub-optimal and patients desired more knowledge. We need deeper understanding of patients’ educational needs related to CRC.

Download Full-text

Inflammatory bowel disease and colonic disorders

Best of Five MCQS for the European Specialty Examination in Gastroenterology and Hepatology ◽

10.1093/oso/9780198834373.003.0007 ◽

2021 ◽

pp. 150-208

Author(s):

Thomas Marjot

Keyword(s):

Colorectal Cancer ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Core Curriculum ◽

Therapeutic Drug ◽

Biologic Therapies ◽

Inflammatory Bowel ◽

Prevention Of Cancer ◽

Curriculum Topics

This chapter covers core curriculum topics relating to inflammatory bowel disease (IBD) and colonic disorders. A diagnostic approach to IBD is covered including the role of imaging, endoscopy, histopathology and clinical features. Pathophysiology and epidemiology of IBD is detailed. Management of Ulcerative colitis and Crohn’s disease includes assessment of disease severity, imaging modalities and therapeutic management. Particular focus is given to therapeutic drug monitoring and indications for biologic therapies. Surgical management of IBD is broadly covered including indications, timing and approach. Coverage is also given to the diagnosis and management of extra-intestinal manifestations of IBD, IBD in special situations (pregnancy, elderly, transition) and the prevention of cancer in IBD. Colorectal cancer and benign conditions including constipation, functional gut disorders and other colitides are also featured.

Download Full-text